0001125345-24-000079.txt : 20240408
0001125345-24-000079.hdr.sgml : 20240408
20240408180730
ACCESSION NUMBER: 0001125345-24-000079
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240404
FILED AS OF DATE: 20240408
DATE AS OF CHANGE: 20240408
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Peters Jeffrey Stuart
CENTRAL INDEX KEY: 0001706903
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36112
FILM NUMBER: 24830676
MAIL ADDRESS:
STREET 1: 9704 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MACROGENICS INC
CENTRAL INDEX KEY: 0001125345
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9704 MEDICAL CENTER DRIVE
CITY: Rockville
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-251-5172
MAIL ADDRESS:
STREET 1: 9704 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
wk-form4_1712614042.xml
FORM 4
X0508
4
2024-04-04
0
0001125345
MACROGENICS INC
MGNX
0001706903
Peters Jeffrey Stuart
9704 MEDICAL CENTER DRIVE
ROCKVILLE
MD
20850
0
1
0
0
Senior VP and General Counsel
1
Common Stock
2024-04-04
4
M
0
42500
4.82
A
51395
D
Common Stock
2024-04-04
4
S
0
42500
15.07
D
8895
D
Common Stock
2024-04-04
4
S
0
147
15.51
D
8748
D
Common Stock
2024-04-04
4
S
0
232
16.38
D
8516
D
Common Stock
2024-04-04
4
S
0
5351
17.74
D
3165
D
Common Stock
2024-04-04
4
S
0
3165
18.22
D
0
D
Employee stock option (right to buy)
4.82
2024-04-04
4
M
0
42500
4.82
D
2033-02-15
Common Stock
42500
127500
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/8/2023.
This transaction was executed in multiple trades at prices ranging from $15.07 to $15.94. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This transaction was executed in multiple trades at prices ranging from $16.01 to $16.58. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This transaction was executed in multiple trades at prices ranging from $17.05 to $17.99. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This transaction was executed in multiple trades at prices ranging from $18.00 to $18.84. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
12.5% of the shares underlying the grant become exercisable 6 months after the 2/15/2023 date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
/s/ Lynn M. Cilinski, Attorney-in-fact
2024-04-08